Navigation Links
LX211 highlighted as potential disease modifying therapy for noninfectious uveitis
Date:10/29/2009

JERSEY CITY, NJ (October 26, 2009): An experimental drug, LX211 (LUVENIQ; oral voclosporin), may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions inevitably associated with either severe vision loss or substantial morbidity from steroid use. Results of international Phase 2/3 clinical trials conducted by Lux Biosciences, to be the subject of two podium presentations at the American Association of Ophthalmology (AAO) meeting and of a presentation at the satellite meeting of the American Uveitis Society (AUS) in San Francisco, October 24-27, highlight the ability of LX211 to control the inflammation that characterizes this potentially blinding eye disease and significantly reduce its rate of recurrence. Lux Biosciences plans to file an NDA and MAA for marketing approvals around year-end 2009 and early 2010 in the United States and Europe, respectively.

"The LX211-02 study was a double-masked, placebo-controlled, dose-ranging study that included 232 patients at 57 centers in North America, Europe and India with clinically inactive uveitis involving any location within the eye," said Bahram Bodaghi, M.D., Ph.D., Piti Salptrire Hospital Paris, France, who will present the study results on Monday October 26 at 8:50 am PT. "Results of this trial showed that LX211 was able to reduce recurrence of inflammation by 50% over placebo at the 0.4 mg/kg twice daily dose (p<0.05) and may therefore effectively increase the interval between inflammatory relapses to 24 months compared to 10 months with placebo."

"Given that inflammatory exacerbation is a direct trigger of vision loss," Prof. Bodaghi commented, "this result for LX211 is impressive. In addition to a marked reduction in recurrence of inflammation, visual acuity was preserved in this study. Moreover, these results suggest the potential for disease modification whereby treatment with LX211 alters the course of the disease leading u
'/>"/>

Contact: Joan Kureczka
JKureczka@comcast.net
415-821-2413
Kureczka/Martin Associates
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels
2. Bio-Matrix Scientific Group, Inc. Highlighted in LifeSciencesWorld.com Special Report; Stem Cell Market Projected to Exceed $8 Billion Worldwide by 2016
3. Inverseons Asthma Therapy Receives Notice of Allowance; Clinical Trial Highlighted in Lancet
4. Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium
5. Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
6. Pressure Cycling Technology (PCT) Highlighted in Five Podium Presentations at the Fifth International Conference on High Pressure; PBI Introduces the Patent-pending PCT Shredder at the Meeting
7. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
8. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
9. Nektars PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress
10. Stereotaxis Market Leadership Highlighted at Heart Rhythm 2008
11. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Aug. 28, 2014   SunTrust Robinson Humphrey ... veterans to its equity research team in biotechnology ... expansion in equity research demonstrates our commitment to ... to enhance their investment decision making," said ... "We continue to make significant investments in differentiated ...
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ( ... novel mid- to late-stage cardiovascular drug candidates, today ... its first round of financing. The Series A ... Hercules Bioventures with participation from investors that included ... executive, Dr. Larry Hsu , the founder ...
(Date:8/28/2014)... Washington, USA (PRWEB) August 27, 2014 ... next month for SPIE Laser Damage 2014 ... optical materials for high-power lasers will run 14-17 September. ... society for optics and photonics . , The premier ... for understanding laser damage to optical materials will engage ...
(Date:8/28/2014)... 2014 Earlier this month, a ... partnership with the U.S. Air Force on the performance ... indicated that this type of fuel made from mustard ... be important to America’s Eco friendly future. In fact, ... mandate to become independent of foreign oil over the ...
Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5
... Software Inc., the leading,provider of web-based employee ... independent research firm Bersin & Associates ranked,Halogen ... its recent report on talent,management vendors. Halogen ... product strength, architecture and customer satisfaction., ...
... BioSeek, Inc. today,announced that Roy A. Whitfield ... of directors. Mr. Whitfield had joined BioSeek,s board ... the Company since November,2005., "Roy,s management experience ... been extraordinarily valuable to BioSeek thus,far. We look ...
... - Oncothyreon Inc. (Nasdaq:,ONTY) (TSX: ONY), a biotechnology ... for the treatment of cancer, today,announced the launch ... ., "We are excited about our new ... which provides additional information about our,product pipeline and ...
Cached Biology Technology:Halogen Receives High Ratings from Bersin & Associates - Company recognized as a market leader, and receives praise for outstanding customer satisfaction 2BioSeek Elects Roy Whitfield Executive Chairman of Board of Directors 2
(Date:8/31/2014)... is available in French . ... just published in the prestigious Nature Neuroscience journal ... Centre of the Douglas Mental Health University Institute and McGill ... circuitry and dynamic mechanisms controlling memory as well of the ... sub-region named the subiculum. , In 2009, they developed ...
(Date:8/29/2014)... Until recently, little has been known about what ... international team of scientists, one of whom is a ... by showing that genes controlling the development of the ... rabbit domestication., The study was published Aug. 28 in ... questions. It is online at http://www.sciencemag.org/ ., The ...
(Date:8/29/2014)... type and number of connections in transcription factor networks ... in a study published in PLOS Computational Biology ... assortativity signature contributes to a network,s resilience against mutations. ... out-out assortativity of TFN models has a greater effect ... types of assortativity," said Dov A. Pechenick, PhD, lead ...
Breaking Biology News(10 mins):Memory and Alzheimer's: Towards a better comprehension of the dynamic mechanisms 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3Assortativity signatures of transcription factor networks contribute to robustness 2
... map data into BiblioSphere , Genomatix Software GmbH ... Science (AAAS) today announced an agreement that allows ... Environment into Genomatix's BibliospherePE pathway knowledge base and ... journal Science, developed the Signal Transduction Knowledge Environment, ...
... of a protein, human CD38, which may lead to important ... in almost every cellular process. The findings also may offer ... to diabetes and HIV-AIDS. , Levels of the ... human CD38 a marker for these diseases. , As ...
... at the National Institute of Child Health and Human ... parasite disperses from the red blood cells it infects. ... Development is one of the Institutes comprising the National ... September 20 Current Biology. , "This discovery provides the ...
Cached Biology News:Genomatix, AAAS ink agreement 2Protein structure key for AIDS, cell function 2Researchers discover how malaria parasite disperses from red blood cells 2Researchers discover how malaria parasite disperses from red blood cells 3
... cyclin required for G1-phase progression and is ... cyclin D2 can phosphorylate pRB when associated ... Human, Mouse, and Rat. Others-not tested. ... suited for neutralization of cyclin D2 activity ...
Mouse Anti-Human Methyl-CpG binding domain protein 2 (MBD2 Monoclonal Antibody Family: Other Applications: Western Blot...
... Synthetic peptide corresponding ... Antigen Family: ... Antigen Subfamily: not ... Recommended Storage: Long ...
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Biology Products: